Related references
Note: Only part of the references are listed.Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials Smoking and immunotherapy efficacy in lung cancer
Ashley M. Hopkins et al.
EUROPEAN JOURNAL OF CANCER (2022)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
Wei Cao et al.
CHINESE MEDICAL JOURNAL (2021)
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
Qiao Liu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
Liu Qiao et al.
FRONTIERS IN PHARMACOLOGY (2021)
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Shun Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
The impact of sex and gender on immunotherapy outcomes
Sabra L. Klein et al.
BIOLOGY OF SEX DIFFERENCES (2020)
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Tina R. Watson et al.
JAMA NETWORK OPEN (2020)
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
Deborah B. Doroshow et al.
CLINICAL CANCER RESEARCH (2019)
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
XiaoMin Wan et al.
JAMA ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
Steven D. Criss et al.
JAMA NETWORK OPEN (2019)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Health state utilities in patients with advanced non-small-cell lung cancer in China
Yunjie Shen et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Health state utilities in non-small cell lung cancer: An international study
Beenish Nafees et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Non-small-cell lung cancer
Cesare Gridelli et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Share Paper
